Gross pathology of left ventricular hypertrophy. Left ventricle is at right in image, serially sectioned from apex to near base.
GLP-1 receptor agonists may benefit patients with moderate concentric left ventricular hypertrophy (LVH) through multiple cardiovascular mechanisms, particularly in those with diabetes, obesity, or established cardiovascular disease, but caution is warranted in patients with heart failure with reduced ejection fraction (HFrEF). 1, 2
Recently, both preclinical studies and clinical observations have shown that the GLP-1 receptor agonist is effective at increasing GLP-1 activity and at protecting the heart against hypertension, hypertrophy and fibrosis, which is beyond the benefits achieved as an anti-diabetic agent [17, 18].
dditionally, experimental evidence from animal models indicates that GLP-1RAs can attenuate left ventricular remodeling, reduce hypertrophy, and enhance diastolic function [37].
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.
Such details provide a deeper understanding and appreciation for Glp-1 Receptor Agonists And Left Ventricular Hypertrophy.
GLP-1RAs contribute to improvements in left atrial (LA) function, atrial fibrillation (AF), blood pressure, blood volume, diastolic function, and cardiac metabolism, while also reducing systemic inflammation, left ventricular (LV) mass, right ventricular (RV) remodeling, and cardiac adiposity.
In this systematic review and meta-analysis, GLP-1RAs were found to have a positive impact on left ventricle diastolic function, hypertrophy, and exercise capacity, but had no effect on systolic function.
As we can see from the illustration, Glp-1 Receptor Agonists And Left Ventricular Hypertrophy has many fascinating aspects to explore.
Underuse of GLP-1 Receptor Agonists in the Management of Type 2...
GLP-1 receptor agonists are key medications for type 2 diabetes and obesity, working to lower blood sugar and aid weight loss by reducing appetite. Always consult a healthcare provider before starting GLP-1s and combine them with a healthy diet and exercise for best results.
